PDF(Pubmed)
Abstract：
Nanoparticles have attracted extensive attention due to their high degree of cell targeting, biocompatibility, controllable biological activity, and outstanding pharmacokinetics. Changing the size, morphology, and surface chemical groups of nanoparticles can increase the biological distribution of agents to achieve precise tissue targeting and optimize therapeutic effects. Examples of their use include nanoparticles designed for increasing antigen-specific immune responses, developing vaccines, and treating inflammatory diseases. Nanoparticles show the potential to become a new generation of therapeutic agents for regulating inflammation. Recently, many nanomaterials with targeted properties have been developed to treat acute lung injury/acute respiratory distress syndrome (ALI/ARDS). In this review, we provide a brief explanation of the pathological mechanism underlying ALI/ARDS and a systematic overview of the latest technology and research progress in nanomedicine treatments of ALI, including improved nanocarriers, nanozymes, and nanovaccines for the targeted treatment of lung injury. Ultimately, these nanomedicines will be used for the clinical treatment of ALI/ARDS.
摘要：
纳米粒子由于其高度的细胞靶向性受到广泛关注,生物相容性，可控的生物活性，和杰出的药代动力学。改变大小，形态学,和纳米颗粒的表面化学基团可以增加药物的生物分布，实现精确的组织靶向和优化治疗效果。其用途的例子包括设计用于增加抗原特异性免疫反应的纳米颗粒，开发疫苗，和治疗炎症性疾病。纳米颗粒显示出成为用于调节炎症的新一代治疗剂的潜力。最近,已经开发了许多具有靶向特性的纳米材料来治疗急性肺损伤/急性呼吸窘迫综合征(ALI/ARDS)。在这次审查中,本文简要阐述了ALI/ARDS的病理机制,系统综述了ALI纳米医学治疗的最新技术和研究进展,包括改进的纳米载体，纳米酶，和纳米疫苗用于肺损伤的靶向治疗。最终,这些纳米药物将用于ALI/ARDS的临床治疗。
